IDXG (Interpace Biosciences) Cyclically Adjusted Book per Share: $0.56 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IDXG Interpace Biosciences Inc IDXG
41 GF Score
Price $1.63
GF Value $0.20
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Interpace Biosciences Cyclically Adjusted Book per Share?

Interpace Biosciences IDXG +3.76% 41 Cyclically Adjusted Book per Share is $0.56 as of Jun. 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Interpace Biosciences's adjusted book value per share for the three months ended in Jun. 2026 was $0.839. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.56 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Interpace Biosciences's average Cyclically Adjusted Book Growth Rate was -91.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -63.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -53.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -37.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Interpace Biosciences was 4.90% per year. The lowest was -63.60% per year. And the median was -19.20% per year.

As of today (2026-08-20), Interpace Biosciences's current stock price is $1.629. Interpace Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $0.56. Interpace Biosciences's Cyclically Adjusted PB Ratio of today is 2.91.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Interpace Biosciences was 2.97. The lowest was 0.01. And the median was 0.04.


Interpace Biosciences  (OTCPK:IDXG) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Interpace Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.629/0.56
=2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Interpace Biosciences was 2.97. The lowest was 0.01. And the median was 0.04.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Interpace Biosciences Cyclically Adjusted Book per Share Related Terms


Interpace Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Interpace Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences Cyclically Adjusted Book per Share Chart

Interpace Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.34 65.61 35.09 12.06 3.16

Interpace Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.72 5.57 3.16 1.66 0.56

IDXG vs PRPO, ADVB, BIOQ: Cyclically Adjusted Book per Share Comparison

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted PB Ratio falls into.


IDXG
41GF Score
Interpace Biosciences Inc IDXG
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interpace Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Interpace Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.839/333.9520*333.9520
=0.839

Current CPI (Jun. 2026) = 333.9520.

Interpace Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 -8.126 241.428 -11.240
201612 29.959 241.432 41.440
201703 36.561 243.801 50.080
201706 18.090 244.955 24.662
201709 15.879 246.819 21.485
201712 14.321 246.524 19.400
201803 14.268 249.554 19.093
201806 13.676 251.989 18.124
201809 12.736 252.439 16.848
201812 5.384 251.233 7.157
201903 9.389 254.202 12.335
201906 8.070 256.143 10.521
201909 6.177 256.759 8.034
201912 -1.142 256.974 -1.484
202003 1.691 258.115 2.188
202006 0.419 257.797 0.543
202009 -5.393 260.280 -6.919
202012 -7.170 260.474 -9.193
202103 -7.998 264.877 -10.084
202106 -8.681 271.696 -10.670
202109 -9.259 274.310 -11.272
202112 -10.112 278.802 -12.112
202203 -10.492 287.504 -12.187
202206 -11.336 296.311 -12.776
202209 -14.506 296.808 -16.321
202212 -14.678 296.797 -16.515
202303 -14.507 301.836 -16.051
202306 -14.430 305.109 -15.794
202309 -14.503 307.789 -15.736
202312 -12.765 306.746 -13.897
202403 -13.972 312.332 -14.939
202406 -13.489 314.175 -14.338
202409 -13.095 315.301 -13.870
202412 -0.503 315.605 -0.532
202503 -0.132 319.799 -0.138
202506 -0.274 322.561 -0.284
202509 -0.067 324.800 -0.069
202512 5.049 324.054 5.203
202603 0.833 330.213 0.842
202606 0.839 333.952 0.839

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.56 mean?
Interpace Biosciences (IDXG) has a Cyclically Adjusted Book per Share of $0.56 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Cyclically Adjusted Book per Share too high?
Interpace Biosciences' current Cyclically Adjusted Book per Share is $0.56. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Cyclically Adjusted Book per Share compare to PRPO and ADVB?
Interpace Biosciences' Cyclically Adjusted Book per Share of $0.56 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Book per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Cyclically Adjusted Book per Share is $0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.63 — trading 714.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $0.56. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Cyclically Adjusted Book per Share is $0.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (IDXG) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of $1.63 is trading 714.5% above its estimated GF Value™ of $0.20. GuruFocus considers Interpace Biosciences to be Significantly Overvalued.

Key valuation signals for IDXG:

  • Cyclically Adjusted Book per Share: $0.56
  • GF Value™: $0.20 vs. price of $1.63 (714.5% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Interpace Biosciences Business Description

Other Exchanges PF42:Germany
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for IDXG

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.63
Price
$0.20
GF Value